11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Camptothecin-based nanodrug delivery systems

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The drug camptothecin has a wide range of antitumor effects in cancers including gastric cancer, rectal and colon cancer, liver cancer, and lung cancer. Camptothecin-based drugs inhibit topoisomerase 1 (Topo 1), leading to destruction of DNA, and are currently being used as important chemotherapeutic agents in clinical antitumor treatment. However, the main obstacle associated with cancer therapy is represented by systemic toxicity of conventional anticancer drugs and their low accumulation at the tumor site. In addition, low bioavailability, poor water solubility, and other shortcomings hinder their anticancer activity. Different from traditional pharmaceutical preparations, nanotechnology-dependent nanopharmaceutical preparations have become one of the main strategies for different countries worldwide to overcome drug development problems. In this review, we summarized the current hotspots and discussed a variety of camptothecin-based nanodrugs for cancer therapy. We hope that through this review, more efficient drug delivery systems could be designed with potential applications in clinical cancer therapy.

          Related collections

          Most cited references59

          • Record: found
          • Abstract: found
          • Article: not found

          Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications.

          Cancer is a leading cause of death worldwide. Currently available therapies are inadequate and spur demand for improved technologies. Rapid growth in nanotechnology towards the development of nanomedicine products holds great promise to improve therapeutic strategies against cancer. Nanomedicine products represent an opportunity to achieve sophisticated targeting strategies and multi-functionality. They can improve the pharmacokinetic and pharmacodynamic profiles of conventional therapeutics and may thus optimize the efficacy of existing anti-cancer compounds. In this review, we discuss state-of-the-art nanoparticles and targeted systems that have been investigated in clinical studies. We emphasize the challenges faced in using nanomedicine products and translating them from a preclinical level to the clinical setting. Additionally, we cover aspects of nanocarrier engineering that may open up new opportunities for nanomedicine products in the clinic.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Polymer conjugates as anticancer nanomedicines.

            The transfer of polymer-protein conjugates into routine clinical use, and the clinical development of polymer-anticancer-drug conjugates, both as single agents and as components of combination therapy, is establishing polymer therapeutics as one of the first classes of anticancer nanomedicines. There is growing optimism that ever more sophisticated polymer-based vectors will be a significant addition to the armoury currently used for cancer therapy.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Inorganic nanoparticles as carriers for efficient cellular delivery

                Bookmark

                Author and article information

                Contributors
                Journal
                Cancer Biol Med
                Cancer Biol Med
                CBM
                Cancer Biology & Medicine
                Chinese Anti-Cancer Association (Tianjing China )
                2095-3941
                November 2017
                : 14
                : 4
                : 363-370
                Affiliations
                [1 ] CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Beijing 100190, China
                [2 ] University of Chinese Academy of Sciences, Beijing 100049, China
                [3 ] College of Biological Science and Engineering, Hebei University of Science and Technology, Shijiazhuang 050018, China
                [4 ] Department of Materials Science and Engineering, Herbert Wertheim College of Engineering, University of Florida, Gainesville, FL 32611, USA
                [5 ] School of Biological Sciences and Medical Engineering, Southeast University, Nanjing 210096, China
                Author notes
                Article
                CBM-2017-0099
                10.20892/j.issn.2095-3941.2017.0099
                5785165
                29372102
                a7fcaa35-67e9-4077-9930-ed154c84cf6e
                History
                : 14 August 2017
                : 9 November 2017
                Categories
                Review

                camptothecins,nanomedicine,cancer therapy,drug delivery system

                Comments

                Comment on this article